Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of XF-73 (exeporfinium chloride) for the prevention of post-surgical infections from all strains of Staphylococcus aureus

Trial Profile

A study of XF-73 (exeporfinium chloride) for the prevention of post-surgical infections from all strains of Staphylococcus aureus

Planning
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Exeporfinium chloride (Primary)
  • Indications Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Destiny Pharma
  • Most Recent Events

    • 12 Apr 2018 According to a Destiny Pharma media release, the company is now finalising plans to start this phase IIb trial.The Company is on track to announce Phase 2b results in the second half of 2019, with the aim of delivering a Phase 3 ready package by the end of 2019.
    • 26 Feb 2018 According to a Destiny Pharma media release, the US FDA has accepted an Investigational New Drug application (IND) for XF-73 that is being developed for the prevention of post-surgical staphylococcal infections such as Methicillin Resistant Staphylococcus aureus (MRSA). Data from this trial is expected in 2019.
    • 18 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top